Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
about
Predicting the presence of hepatitis B virus surface antigen in Chinese patients by pathology data mining.Molecular characteristics of occult hepatitis B virus from blood donors in southeast China.Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion.Hepatitis B virus DNA viral load determination in hepatitis B surface antigen-negative Swiss blood donors.Sensitivity of individual donor nucleic acid testing (NAT) for the detection of hepatitis B infection by studying diluted NAT yield samplesCriteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group.Reducing the risk of hepatitis B virus transfusion-transmitted infectionA comprehensive serological and supplemental evaluation of hepatitis B "seroyield" blood donors: A cross-sectional study from a tertiary healthcare center in India.New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.Hepatitis B virus blood screening: unfinished agendas.Chronic hepatitis B: current epidemiology in the Americas and implications for management.Hepatitis B virus genotypes and evolutionary profiles from blood donors from the northwest region of China.Hepatitis B transmission by cell and tissue allografts: how safe is safe enough?Molecular mechanisms underlying HBsAg negativity in occult HBV infection.Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in Argentina: high rate of recent infections.Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc TestingLiving donor bone banking: processing and discarding--from procurement to therapeutic use.Half a decade of mini-pool nucleic acid testing: Cost-effective way for improving blood safety in India.Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection.The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA.Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay.Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen-positive blood donations.Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests.Occult HBV Infection in NigeriaResidual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives
P2860
Q30647985-F9B61DC4-086C-40C3-BFC4-F3638A73317AQ33627411-05B84FE2-7933-4CA5-932D-85594B6BAB48Q34142175-3CE818EC-CA23-402E-8842-1C74152855C2Q35164580-BD623842-DF01-4535-9E23-239C715AC059Q35265179-FFA95989-3915-4EB6-93F0-D6DFF261D557Q35434455-EFE3CA99-C111-4C9F-B67A-65F12ADCF973Q35683881-1ED781A9-A00E-4834-B209-DC7CFA7521A8Q36034889-388E6E34-AECF-4063-A850-C7F697E41FCAQ36466447-3BC790F1-A24E-4338-AE67-B251BAEA3011Q36498410-9CDE09D4-A3B0-4EF7-8F47-86F04B57C29FQ36655273-D7A0E190-A0CE-4AAF-A858-4E5E38F8F937Q37429620-247BAF73-D12C-40D0-86FE-AFFED96CBA0AQ38223372-01A2E21E-790F-4BBA-A96D-34696940C48CQ38536404-2A745028-74CF-4E49-B576-2195383FA33EQ39131395-AFE3E9EB-FA4A-49EC-9843-B17A477FB7A0Q40383406-2C381245-8981-4E0D-B05E-148B3ECA1347Q40488494-25C5E3E6-282F-42B1-9DD3-345E92D5CBBEQ41111337-2F44DE46-B3FB-4766-8DA6-F77B9A9081DBQ41152008-AADCBB23-847B-4199-9509-A7E40DE30D4BQ42000353-8BCDD1D9-793A-4C70-81A1-C5066C070D78Q42992279-9777DDD2-0AA4-4956-9EF1-5C3C2942DEEEQ42996377-CFED56CC-58CF-467F-B350-BC139D3EF417Q43000009-48B14C43-0B5B-45C3-9FE8-D32E3579801CQ43040836-D38B7D63-FAE1-407B-AB11-571389374B23Q45359766-E228DDB5-91E4-48CD-8DF4-13D6399D5A8FQ45400010-DCA71F5D-C0DD-4274-A773-B62740055B29Q45400011-5F295740-4EF4-40E4-A365-0BD9A203E24EQ45409042-D1FC90C6-1B68-4E0C-89E1-A66106DEFC48Q50722230-BDDEF9A9-C279-4C36-9B18-6519758D2AC0Q56993211-1D06D75F-ACA0-407D-9A55-A8FB255CA14FQ58999805-992123DF-3795-48C6-838D-270B74B98234
P2860
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
@ast
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
@en
type
label
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
@ast
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
@en
prefLabel
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
@ast
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
@en
P1476
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
@en
P356
10.1016/J.TRACLI.2003.12.003
P577
2004-02-01T00:00:00Z